Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection.

AIDS and the bare lymphocyte syndrome (BLS) are severe combined immunodeficiencies. BLS results from mutations in genes that regulate the expression of class II major histocompatibility (MHC II) determinants. One of these is the class II transactivator (CIITA). HIV and its transcriptional transactivator (Tat) also block the expression of MHC II genes. By binding to the same surface in the cyclin T1, which together with CDK9 forms the positive transcription elongation factor b (P-TEFb) complex, Tat inhibits CIITA. CIITA can also activate transcription when tethered artificially to RNA. Moreover, a dominant-negative CDK9 protein inhibits the activity of MHC II promoters. Thus, CIITA is a novel cellular coactivator that binds to P-TEFb for the expression of its target genes.

[1]  R. Kurth,et al.  Decreased accessory cell function of macrophages after infection with human immunodeficiency virus type 1 in vitro , 1990, European journal of immunology.

[2]  J. Chermann,et al.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). , 1983, Science.

[3]  J. Ting,et al.  Two Distinct Gamma Interferon-Inducible Promoters of the Major Histocompatibility Complex Class II Transactivator Gene Are Differentially Regulated by STAT1, Interferon Regulatory Factor 1, and Transforming Growth Factor β , 1999, Molecular and Cellular Biology.

[4]  D. Singer,et al.  Repression of MHC class I gene promoter activity by two-exon Tat of HIV. , 1993, Science.

[5]  E. Unanue.  Antigen-presenting function of the macrophage. , 1984, Annual review of immunology.

[6]  R. Gaynor,et al.  Role of the human and murine cyclin T proteins in regulating HIV-1 tat-activation. , 1999, Journal of molecular biology.

[7]  R. Aebersold,et al.  A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients , 1998, Nature Genetics.

[8]  Emil R. Unanue,et al.  Peptides determine the lifespan of MHC class II molecules in the antigen-presenting cell , 1994, Nature.

[9]  D. Chen,et al.  Specific interaction of Tat with the human but not rodent P-TEFb complex mediates the species-specific Tat activation of HIV-1 transcription. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[10]  B. Peterlin,et al.  The Ability of Positive Transcription Elongation Factor b To Transactivate Human Immunodeficiency Virus Transcription Depends on a Functional Kinase Domain, Cyclin T1, and Tat , 1998, Journal of Virology.

[11]  B. Peterlin,et al.  The class II trans-activator CIITA interacts with the TBP-associated factor TAFII32. , 1997, Nucleic acids research.

[12]  G. Nolan,et al.  Single cell assay of a transcription factor reveals a threshold in transcription activated by signals emanating from the T-cell antigen receptor. , 1990, Genes & development.

[13]  A. Shilatifard.  The RNA polymerase II general elongation complex. , 1998, Biological chemistry.

[14]  E. Verdin,et al.  Histone acetyltransferases regulate HIV-1 enhancer activity in vitro. , 1997, Genes & development.

[15]  M. Merika,et al.  Involvement of CREB Binding Protein in Expression of Major Histocompatibility Complex Class II Genes via Interaction with the Class II Transactivator , 1998, Molecular and Cellular Biology.

[16]  B. Peterlin,et al.  Interactions between the Class II Transactivator and CREB Binding Protein Increase Transcription of Major Histocompatibility Complex Class II Genes , 1999, Molecular and Cellular Biology.

[17]  J. Strominger,et al.  Transactivation by CIITA, the type II bare lymphocyte syndrome-associated factor, requires participation of multiple regions of the TATA box binding protein. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Andrew R. Cherenson,et al.  The structure of an antigenic determinant in a protein , 1984, Cell.

[19]  M Locati,et al.  Chemokines and chemokine receptors: biology and clinical relevance in inflammation and AIDS. , 1999, Annual review of medicine.

[20]  S. Le Gall,et al.  Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. , 1998, Immunity.

[21]  B. Peterlin,et al.  Control of RNA initiation and elongation at the HIV-1 promoter. , 1994, Annual review of biochemistry.

[22]  D. Hazuda,et al.  P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro. , 1997, Genes & development.

[23]  M. Garber,et al.  The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. , 1998, Genes & development.

[24]  B. Peterlin,et al.  Interactions between human cyclin T, Tat, and the transactivation response element (TAR) are disrupted by a cysteine to tyrosine substitution found in mouse cyclin T. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. Singer,et al.  HIV Tat protein requirements for transactivation and repression of transcription are separable. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[26]  B. Cullen,et al.  Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[27]  F. Miedema,et al.  Decreased accessory cell function by human monocytic cells after infection with HIV. , 1988, Journal of immunology.

[28]  T. Walsh,et al.  Impairment of neutrophil chemotactic and bactericidal function in children infected with human immunodeficiency virus type 1 and partial reversal after in vitro exposure to granulocyte-macrophage colony-stimulating factor. , 1990, The Journal of pediatrics.

[29]  P. Marrack,et al.  Superantigens: mechanism of T-cell stimulation and role in immune responses. , 1991, Annual review of immunology.

[30]  B. Walker,et al.  Characterization of HIV-1-specific T-helper cells in acute and chronic infection. , 1999, Immunology letters.

[31]  R. Flavell,et al.  Class II transactivator (CIITA) is sufficient for the inducible expression of major histocompatibility complex class II genes , 1994, The Journal of experimental medicine.

[32]  S. Rowland-Jones,et al.  Broadly cross-reactive HIV-specific cytotoxic T-lymphocytes in highly-exposed persistently seronegative donors. , 1999, Immunology letters.

[33]  H. Gendelman,et al.  Mononuclear phagocytes as targets, tissue reservoirs, and immunoregulatory cells in human immunodeficiency virus disease. , 1992, Current topics in microbiology and immunology.

[34]  B. Peterlin,et al.  Evidence for a trans-acting factor that regulates the transcription of class II major histocompatibility complex genes: genetic and functional analysis. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[35]  B. Mach,et al.  Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome) , 1993, Cell.

[36]  D. Sedmak,et al.  Human Cytomegalovirus Inhibits Major Histocompatibility Complex Class II Expression By Disruption of the Jak/Stat Pathway , 1998, The Journal of experimental medicine.

[37]  F. Miedema.  Immunological abnormalities in the natural history of HIV infection: mechanisms and clinical relevance. , 1992, Immunodeficiency reviews.

[38]  B. Peterlin,et al.  Binding and cooperative interactions between two B cell-specific transcriptional coactivators , 1996, The Journal of experimental medicine.

[39]  G. Pauli,et al.  MHC-Antigens: Constituents of the Envelopes of Human and Simian Immunodeficiency , 1987, Zeitschrift fur Naturforschung. C, Journal of biosciences.

[40]  D. Birmingham,et al.  Cytomegalovirus inhibits major histocompatibility class II expression on infected endothelial cells. , 1994, The American journal of pathology.

[41]  S E Macatonia,et al.  HIV I infection of dendritic cells. , 1990, International reviews of immunology.

[42]  Antonio Lanzavecchia,et al.  Irreversible association of peptides with class II MHC molecules in living cells , 1992, Nature.

[43]  M. Greenberg,et al.  The SH3 domain‐binding surface and an acidic motif in HIV‐1 Nef regulate trafficking of class I MHC complexes , 1998, The EMBO journal.

[44]  R. Gaynor,et al.  Cyclin T1 domains involved in complex formation with Tat and TAR RNA are critical for tat-activation. , 1999, Journal of molecular biology.

[45]  A. Rice,et al.  Targeting of CDK8 to a promoter-proximal RNA element demonstrates catalysis-dependent activation of gene expression. , 1998, Nucleic acids research.

[46]  M. Malim,et al.  The VP16 transcription activation domain is functional when targeted to a promoter-proximal RNA sequence. , 1992, Genes & development.

[47]  L. Glimcher,et al.  Genetic evidence for a new type of major histocompatibility complex class II combined immunodeficiency characterized by a dyscoordinate regulation of HLA-D alpha and beta chains , 1996, The Journal of experimental medicine.

[48]  Martin A. Nowak,et al.  Constant Mean Viral Copy Number per Infected Cell in Tissues Regardless of High, Low, or Undetectable Plasma HIV RNA , 1999, The Journal of experimental medicine.

[49]  B. Mach,et al.  Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1. , 1998, Immunity.

[50]  W. Reith,et al.  Regulation of MHC class II genes: lessons from a disease. , 1996, Annual review of immunology.

[51]  A. McMichael,et al.  T Cell Responses and Viral Escape , 1998, Cell.

[52]  B. Cullen,et al.  Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV‐1 Tat , 1998, The EMBO journal.

[53]  J. Kappes,et al.  Molecular characterization of human immunodeficiency virus type 1 cloned directly from uncultured human brain tissue: identification of replication-competent and -defective viral genomes , 1991, Journal of virology.

[54]  J. Strominger,et al.  Specific complex formation between the type II bare lymphocyte syndrome-associated transactivators CIITA and RFX5. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[55]  A. Pinching,et al.  Antigen-presentation by macrophages but not by dendritic cells in human immunodeficiency virus (HIV) infection. , 1992, Immunology.

[56]  B. Mach,et al.  Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA , 1997, The EMBO journal.

[57]  J. M. Boss,et al.  RFX-B is the gene responsible for the most common cause of the bare lymphocyte syndrome, an MHC class II immunodeficiency. , 1999, Immunity.

[58]  Ping Wei,et al.  A Novel CDK9-Associated C-Type Cyclin Interacts Directly with HIV-1 Tat and Mediates Its High-Affinity, Loop-Specific Binding to TAR RNA , 1998, Cell.

[59]  B. Mach,et al.  Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. , 1994, Science.

[60]  J. Milton,et al.  Identification of multiple cyclin subunits of human P-TEFb. , 1998, Genes & development.